IDRA, IDCD and MDMA Are Not Confirmed Iraqi Authorities

1. Key takeaways

The three authority names IDRA (Iraq Drug Regulatory Authority), IDCD (the drug control and research directorate), and MDMA could not be confirmed, in any directly accessible official source, as having a legal basis of establishment; moh.gov.iq and its legacy mirror were blocked sitewide by Cloudflare during this verification, and the Ministry of Justice site failed to connect. Under evidence discipline, this finding is stated as not found, not as non-existent. The counter-evidence is stronger: the institutional review published in the World Health Organization’s Eastern Mediterranean Health Journal in 2021, volume 27, issue 10, co-authored by the head of the Iraqi pharmacovigilance centre, and the Ministry of Health’s Iraq Pharmaceutical Country Profile 2020, both describe the MOH regulatory architecture in detail and neither mentions IDRA; the architecture they list is the Technical Affairs Directorate (DTA), the Pharmacy Department, the Registration Department, the Iraqi Pharmacovigilance Centre (IPvC), and the National Center for Drug Control and Research. Across its whole site GRZAN uniformly uses the Registration Department of the Technical Affairs Directorate of the Iraqi MOH (DTA), because it traces to two sources: the letterhead of the Registration Department’s own published documents reads Republic of Iraq / Ministry of Health / Technical Affairs Directorate / Registration Department, and the official publication Iraq Pharmaceutical Country Profile 2020 states in section 6.4 that the Registration Department, DTA is responsible for registration of medical products.

• IDRA, IDCD, and MDMA have no confirmable legal basis of establishment in accessible official sources.
• WHO’s 2021 institutional review and the 2020 Pharmaceutical Country Profile describe the MOH architecture without mentioning IDRA.
• GRZAN uses DTA (Registration Department, Technical Affairs Directorate, MOH) uniformly, backed by the department’s letterhead and section 6.4 of the Country Profile.
• IPvC, IPC, and IPhvC are three abbreviations for the same body and must be annotated as such.

2. Legal basis

The documentary record relied on is tabulated below.

Source grade. The WHO paper: primary, verified (full text on the WHO official domain). The Iraq Pharmaceutical Country Profile 2020: primary with indirect verification (hosted on an official domain; the source was intercepted this time and content retrieved through index fragments). The Pharmacy Practice Law No. 40 of 1970: secondary; not to be cited directly as statutory text, the official original not obtained. The Registration Department Drug Registration Regulations: secondary reprint / official publication index level, source unreachable.

Excerpts:

• §6.4: the Registration Department, DTA is responsible for registration of medical products for both private and public sectors whether they are produced nationally or internationally.
• WHO paper: the Pharmacovigilance Centre is part of the Pharmacy Department of the Directorate of Technical Affairs and has been a member of the WHO International Drug Monitoring Programme since 2010.
• Registration Department document B/1: the responsible authority for registration is MOH / technical affairs directorate / registration department.

3. Expert insights

Insight 1: three competing names coexist, plus invented renderings. IDRA, IDCD, and MDMA are routinely presented as Iraq’s device regulator, and Chinese content adds home-made translations of its own. The verification result: none of the three could have its basis of establishment confirmed in directly accessible official sources, and none has a corresponding .gov.iq domain. Because the MOH and Ministry of Justice sites were unreachable, the finding is stated under evidence discipline as not found, not as non-existent. GRZAN still recommends the uniform wording Registration Department of the Technical Affairs Directorate of the Iraqi MOH (DTA), phrased as according to documents published by the Registration Department, never Iraqi law provides; for vigilance matters use the Iraqi Pharmacovigilance Centre (IPvC), noting that this body appears in the same system under three abbreviations, IPC, IPvC, and IPhvC, which denote one institution and must be annotated, or readers will take them for three.

Insight 2: how a mis-transmission grows into multiple independent sources. The typical chain: one English secondary publication, such as a country pharmaceutical law handbook, uses IDRA first; consulting firm websites copy it; Chinese content then re-copies those sites; a search now appears to show three independent sources, all in fact descending from one unsourced secondary publication. The test is simple: trace each source’s citation back and see whether it points to the same secondary publication; if it does, that counts as one source, and the weakest kind.

Insight 3: why the difference between a directorate and an authority matters. The US FDA, China’s NMPA, and Saudi Arabia’s SFDA are regulators with independent legal personality and their own domains, whose decisions can be issued under their own signature; Iraq’s counterpart is a directorate within the ministry, without independent legal personality or its own domain, and the Technical Affairs Directorate site tec-moh.com returned HTTP 500 during verification while the main MOH site was also unreachable. This determines the communication path, to the directorate and its handling desks rather than to an authority’s inbox, and the document form: what you receive are ministerial instructions and directorate notices, not authority orders.

Insight 4: getting an authority name wrong costs more than embarrassment. A wrong regulator name in tender or authorisation documents invites direct challenge to the authenticity of the licence holder; more practically, correspondence or filings addressed to a non-existent body vanish. GRZAN enforces uniform authority names with the Arabic counterpart in all client documents precisely to prevent such low-level but fatal errors.

4. Practical recommendations

• In all GRZAN external documents, tender files, and authorisation letters, the authority name is uniformly the Registration Department of the Technical Affairs Directorate of the Iraqi MOH (DTA); for vigilance matters add a sentence noting that IPvC, IPC, and IPhvC denote the same body.
• Where an authority name supplied by an agent or a tender document shows IDRA, MDMA, or a similar invented name, require the basis of establishment (gazette issue or official .gov.iq page); failing that, tag it as an unverified name in internal material.
• Maintain an authority name crosswalk as a template: Chinese name, Arabic original, English full name, parent ministry, independent legal personality yes or no. Deliver it to the client team at project start.
• Keep the Arabic authority name in all external correspondence to prevent drift through back-translation. Practical estimate: dealings with directorates rely mainly on telephone and in-person follow-up; email response rates are unstable (no official service commitment provision found).
• Review the institutional architecture periodically. Practical estimate: a semi-annual review is recommended (no official provision found); trigger conditions are restoration of MOH website access or a new country profile edition.

5. Verification checklist

• □ Download the WHO paper full text from the WHO EMRO official domain (applications.emro.who.int) and confirm the architecture description and author affiliations.
• □ Search the paper’s full text for the string IDRA and confirm zero hits.
• □ Access moh.gov.iq or its legacy mirror to download the original Iraq Pharmaceutical Country Profile 2020 and verify the §6.4 wording.
• □ Search .gov.iq sitewide and the Iraqi Official Gazette for IDRA and MDMA and confirm zero results.
• □ Check whether the Technical Affairs Directorate site tec-moh.com is restored, and on restoration request the organisation chart and contact list.
• □ Search the Ministry of Justice gazette library for the original Pharmacy Practice Law No. 40 of 1970 and confirm its provisions on marketing authorisation and scientific offices.
• □ Recheck whether the official documents cited here have been superseded by later instructions or decisions (verification date for this article: 29 October 2026).

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Iraqi market. Our team manages KMOC (Kurdistan) and federal MOH registration procedures, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com